✦ LIBER ✦

Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics

✍ Scribed by John D. Hines; David J. Adelstein; Jeffrey L. Spiess; Paul Giroski; Susan Gear Carter

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 457 KB
Volume: 63
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19890315)63:6+<1022::aid-cncr2820631306>3.0.co;2-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bimonthly high dose leucovorin and 5-flu

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma

✍ Karine Beerblock; Yves Rinaldi; Thierry André; Christophe Louvet; Eric Raymond; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly

Phase II study of oral eniluracil, 5-flu

Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma

✍ Neal J. Meropol; Donna Niedzwiecki; Donna Hollis; Richard L. Schilsky; Robert J. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Hypocalcemia associated with 5-fluoroura

Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas

✍ Yuichiro Kido; Takeshi Okamura; Morimasa Tomikawa; Manabu Yamamoto; Morio Shirai 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 2 views

## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen

Bimonthly high dose leucovorin and 5-flu

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma

✍ Christophe Tournigand; Christophe Louvet; Aimery de Gramont; Elisabeth Lucchi; J 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] õ 1.75 m 2 ) or 4.5 MU (BSA ¢ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'O

A simplified regimen of weekly high dose

A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma

✍ Tsai-Shen Yang; Kuan-Cheng Hsu; Jy-Ming Chiang; Reiping Tang; Jinn-Shium Chen; C 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## BACKGROUND. Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. In this study, a simplified regimen of weekly

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer